Ninety percent of people with Down syndrome, also known as trisomy 21, will develop Alzheimer’s, yet this population has never been included in the clinical research that has underpinned regulatory approvals for the medicines to help treat it.
AC Immune is currently the only prominent company working specifically with these patients and in January, the company began enrolling a cohort of people with Down syndrome in the phase 1/2 ABATE trial, which is testing the vaccine ACI-24.060. The vaccine is designed to stimulate the immune system to produce antibodies against a build-up of the protein Abeta (Aβ) in the brain.
Part 1 of the ABATE study is recruiting volunteers aged 50-75 with early-stage Alzheimer’s disease and opened last week at the CRF .
They have been approved for Part 2 of the study and will be recruiting people with Down’s syndrome, working with the Learning Disability team in Oxford Health, for the first time, offering research to adults with Down’s Syndrome.
We are sorry you did not find this page helpful
Tell us how we can improve this page
Published: 22 March 2023